From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Presidential highlights
Prof Patrick Neven, a distinguished gynaecological oncologist affiliated with UZ Leuven in Belgium, provided an account of the TROPION BreastO1 study during the presidential symposium at ESMO 2023. The study,
Daily highlights in breast cancer
Mounting evidence indicates a connection between breast cancer risk and outdoor air pollution, a link previously established for lung cancer. However, establishing this association for breast cancer has been challenging
The latest findings from the Survival Update of the DESTINY-Breast04 trial were presented, focusing on the comparison between trastuzumab deruxtecan (T-DXd) treatment and physician’s choice treatment in HER2-low unresectable/metastatic breast
During the session, updated findings from the BEGONIA trial were unveiled, centering on an investigation into the effectiveness of a novel TROP2-directed Antibody Drug Conjugate (ADC) named datopotamab deruxtecan (Dato-DXd)
Prof Neven from KU Leuven reports on the proferred papers on early stage Breast Cancer that were reported the first day of the congress.
The first presentation by Prof Nadia
In-depth stories about breast cancer
Dr Eline Naert, a medical oncologist at Ghent University Hospital interviews Prof Philip Poortmans from the Iridium Netwerk and University of Antwerp who was invited to share the perspective of
The TULIP trial represents a pivotal phase 3 study conducted to assess the efficacy of trastuzumab duocarmazine (T-Duo) in patients suffering from metastatic breast cancer with HER2 overexpression. In this
During ESMO 2023 Prof Hurwitz, affiliated with the Fred Hutch Cancer Center in Seattle, discussed with Dr Eline Naert from UZ Ghent the pooled analysis of the DESTINY Breast 01,
In this insightful discussion between Dr Eline Naert, a medical oncologist from Ghent University Hospital and Prof Evandro de Azambuja, medical oncologist from the Institut Bordet, Brussels, the focus revolves
In a discussion at ESMO between Dr Eline Naert, medical oncologist from Genth University Hospital and Prof Evandro De Azambuja from Institut Jules Bordet, the focus was on the Keynote
In this discussion, Dr Eline Naert, a medical oncologist at Ghent University Hospital, and Dr Caroline Duhem, from Centre Hospitalier de Luxembourg, explored the five-year efficacy outcomes of the monarchE
In this discussion, Dr Eline Naert, a medical oncologist at Ghent University Hospital, and Dr Kevin Punie, from GZA Antwerp, delve into the five-year event-free survival analysis of the KEYNOTE
Breast cancer poster selection
Dr Joris, medical oncologist at UZ Brussels and Prof Decoster, medical oncologist at UZ Brussels gave a summary of the 2 posters they presented.
Efficacy of olaparib in advanced cancers
Dr Philippe Aftimos, medical oncologist at Jules Bordet Institut Brussels, summarizes the poster he presented.
GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION
Prof Patrick Neven, gynaecological oncologist at University Hospital Leuven, summarizes the poster he presented.
A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER- early breast cancer (EBC): Final analysis
Dr. Kevin Punie, medical oncologist at GZA hospitals in Wilrijk presented a retrospective observational analysis evaluating real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer
With the educational support of: